Stock A003520 YUNGJIN PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Yungjin Pharm. Co., Ltd.

Equities

A003520

KR7003520004

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-07-07 EDT 		5-day change 1st Jan Change
2,180 KRW +0.93% Intraday chart for Yungjin Pharm. Co., Ltd. +4.31% +2.59%
2023 Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors CI
2023 Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors
CI
Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors
CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from KOSPI 200 Index
CI
Yungjin Pharm : signed a collaborative research agreement with Curome for treatment of rare mitochondrial disease
PU
Yungjin Pharm : Abliva announces positive clinical phase 1a/b results in PMD patients for KL1333 that has been in-licensed from Yungjin
PU
Yungjin Pharm : Family-Friendly certification proves that Yungjin Pharmaceutical is a great place to work
PU
Neurovive and Yungjin Report Positive KL1333 Phase I Clinical Study Results Paving the Way for Further Clinical Development
CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Completes the Clinical Phase I Single Ascending Dose Study of KL1333
CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Report Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333
CI
LG Ro Local Housing Association completed the acquisition of land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd..
CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Announce Clinical Phase I Study of KL1333
CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Enters into Global Licensing Agreement on Yungjin Pharm's Compound KL333
CI
Yungjin Pharm. Co., Ltd. completed the acquisition of KT&G Life Sciences.
CI
LG Ro Local Housing Association signed a contract to acquire land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd. for KRW 21.4 billion.
CI
Yungjin Pharm. Co., Ltd. agreed to acquire KT&G Life Sciences for KRW 87.4 billion.
CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from Russell Global Index
CI
Haitai Beverage Co., Ltd. completed the acquisition of the assets of drink business unit from Yungjin Pharm. Co., Ltd..
CI
Haitai Beverage Co., Ltd. agreed to acquire the assets of drink business unit from Yungjin Pharm. Co., Ltd. for KRW 7.1 billion.
CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) added to KOSPI 200 Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A003520 Stock
  4. News Yungjin Pharm. Co., Ltd.